CSIMarket
 
Zentalis Pharmaceuticals Inc   (ZNTL)
Other Ticker:  
 
 
Price: $14.3200 $0.22 1.524%
Day's High: $14.69 Week Perf: 2.73 %
Day's Low: $ 13.71 30 Day Perf: 19.83 %
Volume (M): 2,308 52 Wk High: $ 31.46
Volume (M$): $ 33,051 52 Wk Avg: $19.58
Open: $14.08 52 Wk Low: $9.56



 Market Capitalization (Millions $) 936
 Shares Outstanding (Millions) 65
 Employees 105
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -292
 Cash Flow (TTM) (Millions $) -15
 Capital Exp. (TTM) (Millions $) 1

Zentalis Pharmaceuticals Inc
Zentalis Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company that specializes in developing small molecule drugs for the treatment of cancer. The company was founded in 2014 and is headquartered in New York City, USA.

The company's primary focus is on developing cancer therapies that target specific protein biomarkers expressed by tumor cells. Zentalis Pharmaceuticals has a proprietary drug discovery platform that it uses to identify new targets and create optimized drug candidates for clinical development.

The company's pipeline is focused on several clinically validated targets, including BCL-2 inhibitor, WEE1 kinase inhibitor and SHP2 inhibitor. The company's lead compounds are ZN-c5 and ZN-c3, which target BCL-2 and WEE1 kinases, respectively. Both of these targets have been shown to be important in the survival and proliferation of cancer cells.

Zentalis Pharmaceuticals is also developing a portfolio of SHP2 inhibitors, including ZN-449, which has shown promising results in preclinical models of cancer. SHP2 is a critical regulator of downstream signaling pathways that are commonly dysregulated in cancer, making it an attractive target for drug development.

The company has a strong team of scientific and clinical leaders with deep experience in the pharmaceutical industry. Their expertise includes oncology drug development, clinical trial design and execution, and regulatory affairs.

Overall, Zentalis Pharmaceuticals Inc. is well-positioned to advance its pipeline of cancer therapies through clinical development and ultimately commercialization. Its meaningful collaborations with leading academic research institutions and experienced team of experts, along with its cutting-edge drug discovery platform, make it an attractive partner for collaboration and investment in the fight against cancer.


   Company Address: 1359 Broadway New York 10018 NY
   Company Phone Number: 433-3791   Stock Exchange / Ticker: NASDAQ ZNTL
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Shares

Zentalis Pharmaceuticals Expands Team with Inducement Stock Options, Driving Growth in Outstanding Shares

Published Fri, Mar 1 2024 11:00 PM UTC

Zentalis Pharmaceuticals Grants Inducement Stock Options to New Hires, Adding to Total Outstanding Shares
In recent months, Zentalis Pharmaceuticals Inc. has been actively engaging in inducement grants under Nasdaq Listing Rule 5635(c)(4) to attract top talent to their team. On March 1, 2024, the Compensation Committee of Zentalis' Board of Directors granted non-qualifie...

Zentalis Pharmaceuticals Inc

Major Pharmaceutical Preparations Industry Faces Challenges with Operating Shortfall in Q4 2023

The Major Pharmaceutical Preparations industry is currently facing significant challenges, as highlighted by the recent earnings report of Zentalis Pharmaceuticals Inc. These financial results have raised concerns among industry insiders and investors, indicating a bearish outlook for the company and potentially for the entire sector.
One alarming aspect of the earnings report is the operating shortfall of $-67.922 million observed by industry insiders. This shortfall indicates that Zentalis Pharmaceuticals Inc has not generated sufficient revenue to cover its operating expenses during the fourth quarter of 2023. Furthermore, the company has not mentioned any top-line figures, signaling a lack of growth and potential stagnation in its business performance.

Shares

Zentalis Pharmaceuticals Grants Generous Stock Options and Restricted Stock Units, Attracting Top Talent and Driving Innovation in Cancer Therapeutics

Published Thu, Feb 1 2024 10:00 PM UTC



In a strategic move aimed at bolstering its clinical development pipeline, Zentalis Pharmaceuticals, a leading clinical-stage biopharmaceutical company, announced the granting of non-qualified stock options and restricted stock units to six newly hired employees. The move comes as part of their 2022 Employment Inducement Incentive Award Plan, signaling the company'...

Management Changes

Zentalis Pharmaceuticals Appoints Accomplished Oncologist, Dr. Diana Hausman, as Chief Medical Officer in a Bid to Overcome Market Downturn.

Published Thu, Jan 25 2024 12:00 PM UTC

Zentalis Pharmaceuticals Bolsters Leadership Team and Aims to Reverse Market Downturn
In an effort to navigate through a challenging market period, Zentalis Pharmaceuticals Inc. has made significant strides in strengthening its management team with key appointments. The company has recently announced the addition of Dr. Diana Hausman, an accomplished oncologist and drug ...

Shares

Zentalis Pharmaceuticals Empowers New Employee with Stock Options and Restricted Stock Units, Furthering Commitment to Advancing Cancer Therapy.

Published Fri, Dec 1 2023 10:39 PM UTC

Zentalis Pharmaceuticals Grants Stock Options and Restricted Stock Units to New Employee in Line with Nasdaq Listing Rules.
New York, NY, and San Diego, CA - December 1, 2023 - Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a pioneering clinical-stage biopharmaceutical company focused on developing innovative small molecule therapeutics for cancer, today announced that i...






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com